Carreno M, Yang W C, Esquenazi V, Fuller L, Burke G, Milgrom M, Roth D, Ranjan D, Miller J
Department of Surgery, Miami Veterans Hospital, Florida.
Transplantation. 1990 Feb;49(2):408-15. doi: 10.1097/00007890-199002000-00036.
Four of 21 renal transplant recipients treated with OKT3 for rejection episodes developed a second sustained (approximately 2 weeks) depression in CD3 peripheral blood lymphocyte cell-surface-marker expression. This occurred after OKT3 therapy had ceased, subsequent to a return toward baseline CD3 levels seen before OKT3 therapy was instituted. The second decrease in CD3 T cell counts was dissociated from CD2 marker T cell counts using flow cytometry and coincided with transient cytomegaloviral infections. Three phases of immunosuppression were defined in these 4 patients: phase I (during OKT3 treatment); phase II (after treatment when CD3 counts were reconstituted); and phase III (when CD3 counts again were depressed). During phase III, serum of the 4 affected patients could transfer a blocking effect on the expression of the CD3 marker of peripheral blood T cells of "normal" laboratory volunteers. Contained in these sera were human IgG antibodies that bound on Western blot analysis and by radioautography after immunoprecipitation to a protein band of a T cell membrane lysate with an m.w. of 23 kD. The reaction was identical to that seen with OKT3 (immunoprecipitation). Moreover, this Western blot binding could be virtually (but not completely) eliminated by multiple absorptions of the T cell membrane lysate with OKT3. By using an affinity-purified human anti-OKT3 IgG from one of the 4 patients, it was possible to immunoabsorb from phase III sera the CD3 blocking activity as well as the binding to the 23 KD protein band. A reverse immune absorption by the phase III sera with the anti-OKT3 IgG after ultracentrifugation prevented the anti-OKT3 IgG from binding to OKT3 coated plates in solid-phase radioimmunoassay. These data support the notion that autoimmune human anti-anti-id (Ab2) antibodies can occasionally be generated by treatment with OKT3, which are directed against CD3 complex epitopes similar to the ligand of OKT3.
接受OKT3治疗排斥反应的21例肾移植受者中,有4例出现外周血淋巴细胞表面标志物CD3表达再次持续下降(约2周)。这种情况发生在OKT3治疗停止后,此前CD3水平已恢复至OKT3治疗开始前的基线水平。利用流式细胞术分析发现,CD3 T细胞计数的第二次下降与CD2标志物T细胞计数无关,且与短暂的巨细胞病毒感染同时发生。这4例患者被确定经历了三个免疫抑制阶段:I期(OKT3治疗期间);II期(治疗后CD3计数恢复时);III期(CD3计数再次下降时)。在III期,4例受影响患者的血清能够对外周血T细胞的CD3标志物表达产生阻断作用。这些血清中含有人类IgG抗体,经免疫沉淀后,通过蛋白质印迹分析和放射自显影发现,该抗体与分子量为23 kD的T细胞膜裂解物蛋白条带结合。此反应与OKT3(免疫沉淀)所见相同。此外,通过用OKT3多次吸附T细胞膜裂解物,这种蛋白质印迹结合几乎(但并非完全)可以消除。使用从4例患者之一中亲和纯化的人抗OKT3 IgG,能够从III期血清中免疫吸附CD3阻断活性以及与23 KD蛋白条带的结合。超速离心后的III期血清与抗OKT3 IgG进行反向免疫吸附,可阻止抗OKT3 IgG在固相放射免疫测定中与包被OKT3的平板结合。这些数据支持这样一种观点,即使用OKT3治疗偶尔可产生针对与OKT3配体相似的CD3复合表位的自身免疫性人类抗独特型抗体(Ab2)。